The most common mTOR inhibitors are temsirolimus and everolimus used for different types of cancer such as HER2-negative breast cancer, pancreatic neuroendocrine tumors, estrogen-receptor-positive, and renal-cell carcinoma (92–94). Here, ERBB2 is linked to breast carcinoma.